ZLDA.F Stock Overview
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Zelira Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.48 |
| 52 Week High | AU$1.65 |
| 52 Week Low | AU$0.47 |
| Beta | 0.52 |
| 1 Month Change | -9.57% |
| 3 Month Change | -20.62% |
| 1 Year Change | n/a |
| 3 Year Change | -93.90% |
| 5 Year Change | -91.98% |
| Change since IPO | -93.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZLDA.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.01% | 2.0% |
| 1Y | n/a | 9.5% | 22.3% |
Return vs Industry: Insufficient data to determine how ZLDA.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ZLDA.F performed against the US Market.
Price Volatility
| ZLDA.F volatility | |
|---|---|
| ZLDA.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZLDA.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ZLDA.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Oludare Odumosu | zeliratx.com |
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology.
Zelira Therapeutics Limited Fundamentals Summary
| ZLDA.F fundamental statistics | |
|---|---|
| Market cap | US$5.23m |
| Earnings (TTM) | -US$23.80m |
| Revenue (TTM) | US$182.24k |
28.7x
P/S Ratio-0.2x
P/E RatioIs ZLDA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZLDA.F income statement (TTM) | |
|---|---|
| Revenue | AU$278.90k |
| Cost of Revenue | AU$358.24k |
| Gross Profit | -AU$79.34k |
| Other Expenses | AU$36.35m |
| Earnings | -AU$36.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.21 |
| Gross Margin | -28.45% |
| Net Profit Margin | -13,062.44% |
| Debt/Equity Ratio | -68.8% |
How did ZLDA.F perform over the long term?
See historical performance and comparison